Compare CBRL & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBRL | FLGT |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.7M | 525.3M |
| IPO Year | 1998 | 2016 |
| Metric | CBRL | FLGT |
|---|---|---|
| Price | $27.71 | $15.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $36.89 | $28.33 |
| AVG Volume (30 Days) | ★ 1.0M | 606.6K |
| Earning Date | 03-04-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ 12.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,030,445,000.00 | $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | $3.62 | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $24.85 | $13.46 |
| 52 Week High | $68.09 | $31.04 |
| Indicator | CBRL | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 44.74 |
| Support Level | $25.52 | $15.39 |
| Resistance Level | $29.87 | $16.88 |
| Average True Range (ATR) | 1.34 | 0.69 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 33.33 | 56.51 |
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.